South Korean biotechnology company develops international distribution, education and market-development activities for its biomaterials portfolio
-- ABio Materials Co., Ltd., a South Korean biotechnology company specializing in exosomes and biomaterials, announced the continued international expansion of its Celexo professional aesthetics portfolio.
The company has developed an integrated technology platform encompassing research, extraction, stabilization, formulation and manufacturing. Its technologies include ExoTraction, an exosome extraction platform, and Cellularsome, a particle-stabilization technology used in the development of selected formulations.
ABio Materials is developing Celexo as a professional aesthetics platform supported by its research into exosomes, PDRN, collagen and other biomaterials.
The company’s portfolio includes Celexo Exo-Cica, a professional-use formulation containing Centella-derived exosome ingredients; CellExosome Black Label Skin, formulated with human adipose-derived extracellular vesicle ingredients; and CellExosome Black Label Hair, developed for professional scalp and hair care.
Product classification, availability and permitted applications vary by country and jurisdiction. Products are introduced in individual markets in accordance with applicable local requirements.
International Market Development
ABio Materials has been developing its international presence through distributor relationships, professional education programs and participation in medical aesthetics events.
The company has presented its technologies and product portfolio at the IMCAS World Congress in Paris, IMCAS Americas in São Paulo and International Beauty Expo Malaysia. These events provided opportunities to meet physicians, aesthetics professionals and prospective distribution partners from several international markets.
ABio Materials is also pursuing applicable product registrations and distribution arrangements in selected markets across Europe, Southeast Asia and the Middle East.
In North America, ABio Materials USA Inc. serves as the company’s local business base and supports market development, professional education and permitted distribution activities. The company is also developing business relationships across Europe, the Middle East, Asia and the Americas.
The international expansion forms part of ABio Materials’ strategy to develop a diversified portfolio of professional aesthetics products based on its biomaterial research and formulation platforms.
“The professional aesthetics sector is increasingly examining the technologies, formulations and scientific processes associated with biomaterial-based products,” an ABio Materials representative said. “Our objective is to expand Celexo’s international presence while continuing to develop the portfolio through our biotechnology research and manufacturing capabilities.”
ABio Materials plans to continue developing its international distribution and professional network while conducting research and product-development activities involving exosomes, PDRN, collagen and other biomaterials.
About ABio Materials Co., Ltd.
ABio Materials Co., Ltd. is a South Korean biotechnology company involved in the research and development of exosomes, PDRN and other biomaterials for the professional aesthetics and cosmetics industries. The company develops professional skin and hair care formulations under the Celexo and CellExosome brands. ABio Materials USA Inc. supports the company’s business activities in North America.
Product availability, regulatory status and permitted uses vary by jurisdiction. References to products or ingredients in this announcement do not constitute medical advice or claims that any product diagnoses, treats, cures or prevents a disease or medical condition.
Company video: https://www.youtube.com/watch?v=a4EVyNigK48
Telephone: +82 2-6959-3734
Celexo: https://celexo.co.kr
Contact Info:
Name: Sukhyung Choi
Email: Send Email
Organization: ABio Materials Co., Ltd.
Website: https://a-bio.co.kr
Release ID: 89200040
In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.
